CELLphenomics is a functional precision medicine company that leverages automation to perform drug sensitivity screening on fresh primary patient PD3D samples. At CELLphenomics, we use this state-of-the-art technology to determine what types of novel drugs and drug combinations might be useful to future patients with solid cancers such as triple negative breast cancer (TNBC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
For biotech and pharmaceutical companies, we leverage our platform to predict responses to potential therapies and determine which will be most effective for specific cancers. Our work is centered around identifying the right patient population to enhance selection for potential clinical trials, effective drug combinations, and biomarkers to enable pharmaceutical companies to get new therapies to patients faster.
CELLphenomics was founded by Christian Regenbrecht and Quirin Graf Adelmann. Since then, CELLphenomics has grown into a company on the verge of transforming the way we develop cancer drugs and identify therapies for patients with solid cancers.